Cover Image

Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma

Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idaru...

Full description

Saved in:
Bibliographic Details
Main Authors: Auel, Britta (Author) , Goldschmidt, Hartmut (Author) , Möhler, Thomas (Author)
Format: Article (Journal)
Language:English
Published: 2012
In: Indian journal of hematology and blood transfusion
Year: 2011, Volume: 28, Issue: 2, Pages: 67-76
ISSN:0974-0449
DOI:10.1007/s12288-011-0103-1
Online Access:Volltext
Get full text
Author Notes:Britta Auel, Hartmut Goldschmidt, Thomas Geer, Thomas M. Moehler, Uwe Platzbecker, Ralph Naumann, Igor Blau, Mathias Hänel, Wolfgang Knauf, Holger Nückel, Hans-Jürgen Salwender, Christof Scheid, Katja Weisel, Marcus Gorschlüter, Axel Glasmacher, Ingo G.H. Schmidt-Wolf, The German Refractory Myeloma Study Group
Description
Summary:Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idarubicin, dexamethasone) or with VRID (vinorelbine, idarubicin, dexamethasone) for relapsed or refractory multiple myeloma. In total, 197 patients were enrolled in multicenter trials. After matching for important prognostic variables 46 matched-pairs (total of 138 patients) could be analysed with regard to survival, toxicity and efficacy. Interestingly, a significant improvement of overall response rate (ORR) for TCID treatment compared to VID and VRID was found. In addition, TCID treatment also led to a significantly higher overall survival (OS) as well as progression-free survival (PFS) compared to VID and VRID. In conclusion, TCID treatment appears to be superior to VRID and VID treatment in patients with progressive or refractory myeloma.
Item Description:Published online: 18 August 2011
Gesehen am 22.08.2018
Physical Description:Online Resource
ISSN:0974-0449
DOI:10.1007/s12288-011-0103-1

Similar Items